捷利交易寶(08017.HK)年度實現純利1302.51萬港元
格隆匯 6 月 19日丨捷利交易寶(08017.HK)發佈公告,截至2020年3月31日止年度,實現收益5175.27萬港元,同比增加約11.7%;溢利為1302.51萬港元,上年同期虧損1769.77萬港元;每股基本盈利為2.74港仙;不派末期股息。
公告表示,集 團於報告期間的收益增加主要歸因於增值服務收益增加。集團於報告期間的直接成本為1498.2萬港元(同期:1128.42萬港元),較同期增加32.8%。集團於報告期間的直接成本增加主要由於為優化後台管理軟件系統而購買由一名第三方提供的技術服務,以提升交易寶公版穩定性及改進新股通、iBroker、打新記的用户體驗所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.